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Abstract
The treatment effect in a specific subgroup is often of interest in randomized
clinical trials. When the subgroup is characterized by the absence of certain post-
randomization events, a naive analysis on the subset of patients without these events
may be misleading. The principal stratification framework allows one to define an
appropriate causal estimand in such settings. Statistical inference for the principal
stratum estimand hinges on scientifically justified assumptions, which can be included
with Bayesian methods through prior distributions. Our motivating example is a large
randomized placebo-controlled trial of siponimod in patients with secondary progressive
multiple sclerosis. The primary objective of this trial was to demonstrate the efficacy
of siponimod relative to placebo in delaying disability progression for the whole study
population. However, the treatment effect in the subgroup of patients who would not
relapse during the trial is relevant from both a scientific and regulatory perspective.
Assessing this subgroup treatment effect is challenging as there is strong evidence that
siponimod reduces relapses. Aligned with the draft regulatory guidance ICH E9(R1),
we describe in detail the scientific question of interest, the principal stratum estimand,
the corresponding analysis method for binary endpoints and sensitivity analyses.
Keywords: Bayesian analysis, causal inference, clinical trial, estimand, identification, sub-
group.
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1 Introduction
Assessments of the treatment effect in specific subgroups often guide decisions regarding
product labeling, reimbursement and clinical practice. Yusuf et al. (1991) distinguish be-
tween two types of subgroups in randomized clinical trials: “proper subgroups” characterized
by baseline data, and “improper subgroups” characterized by post-randomization data. For
“improper subgroups”, a naive analysis would compare test and control treatment in patients
observed to fall into the subgroup. Such analyses may be misleading as post-randomization
data are potentially affected by treatment. Nevertheless, subgroups characterized by post-
randomization data continue to be of scientific, regulatory and practical interest (Hirji and
Fagerland, 2009; Bohula et al., 2015; Ridker et al., 2018).
In a seminal paper, Frangakis and Rubin (2002) proposed principal stratification to
overcome the issues with “improper subgroups”. In this framework, questions related to such
subgroups are expressed in the language of potential outcomes (Neyman, 1923; Rubin, 1974).
For each patient, we envisage his/her potential post-randomization data when randomized to
test and control treatment, respectively. The principal strata then consist of those patients
which would fall into subgroups defined by different combinations of their potential outcomes.
As potential outcomes can be seen as baseline covariates, the principal stratum is a “proper
subgroup”, and hence the treatment effect in this subgroup, the principal stratum effect, has
a causal interpretation.
Statistical inference is challenging as the principal stratum effect is not fully identifiable
from the observed data without additional assumptions. In the following, we use a Bayesian
model-based approach for which partial identifiability causes no real difficulty (Lindley,
1972). In the Bayesian approach, substantive assumptions are transparently introduced
through priors on model parameters, which can be changed in sensitivity analyses. A tutorial
on principal stratification is provided by Egleston et al. (2010), and recent research includes
Baccini et al. (2017), Ding and Lu (2017), and Egleston et al. (2017).
Principal stratification is one of five strategies described in the draft regulatory guidance
document ICH E9(R1) on estimands and sensitivity analyses in clinical trials (ICH, 2017).
The approach is also discussed in the NRC (2010) report commissioned by the FDA. However,
experience with the principal stratification framework in a regulatory context is currently
very limited. In the following, we describe a case study where this framework was used to
address a key regulatory question regarding product labeling. This should facilitate further
innovative applications of this framework by practitioners.
Our motivating example is the EXPAND study, a large placebo-controlled trial of sipon-
imod in patients with secondary progressive multiple sclerosis (NCT01665144 on Clinical-
Trials.gov). The primary objective of this trial was to demonstrate the efficacy of siponimod
relative to placebo in delaying disability progression, which was achieved (Kappos et al.,
2018). However, the treatment effect in the subgroup of patients who would not relapse
during the trial is relevant from both a scientific and regulatory perspective. Assessing this
subgroup treatment effect is challenging as there is strong evidence that siponimod reduces
relapses (Selmaj et al., 2013; Kappos et al., 2018).
In Section 2 we discuss in more detail the EXPAND study and the scientific question
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of interest. The principal stratum estimand and scientific assumptions for identification are
described in Section 3. Section 4 provides the Bayesian analysis model and methods for
sensitivity analysis. Case study results are then shown in Section 5. The article closes with
a discussion (Section 6). Software code for the main analysis is provided as supplementary
information.
2 Motivating case study - the EXPAND trial
EXPAND was a randomized, double-blind, placebo-controlled, event- and exposure-driven
phase 3 study evaluating the efficacy of siponimod in patients with secondary progressive
multiple sclerosis (SPMS). 1651 patients were randomized in a 2:1 ratio to receive once-daily
2mg siponimod or placebo. The primary objective was to demonstrate efficacy of siponimod
relative to placebo in delaying the time to 3-month confirmed disability progression (CDP)
as measured by the Expanded Disability Status Scale (EDSS). The EDSS is an ordinal scale
used for assessing neurologic impairment in MS based on a neurological examination. It
combines scores in seven functional systems and an ambulation score, and ranges from 0 (no
impairment) to 10 (death due to MS). 3-month CDP is defined by a pre-specified increase
from EDSS baseline that is subsequently sustained for at least 3 months. The study achieved
its objective with an estimated hazard ratio of 0.79 (95% CI: 0.65–0.95). Full study results
are reported in Kappos et al. (2018).
While relapses in SPMS are relatively infrequent compared to the preceding relapsing-
remitting disease stage, some patients did experience relapses during the study. During these
relapses, patients experience an increased EDSS score from which they may fully or partly
recover (a CDP confirmation may not take place during a relapse). As expected based on
prior trials (Selmaj et al., 2013), siponimod also substantially reduced the annualized relapse
rate with a rate ratio of 0.45 (95% CI: 0.34–0.59). This raised the question of siponimod’s
ability to delay CDP unrelated to its effect on relapses. Of particular interest was the effect
of siponimod among the subgroup of patients for whom relapses would be absent during the
study.
Special care must be taken when defining a treatment effect through such a subgroup,
since naive classification based simply on absence of on-study relapses would constitute an
“improper” subgroup, defined by post-randomization outcomes that are affected by treat-
ment. To overcome this issue, a principal stratum estimand was defined as the relative effect
of treatment on the occurrence of 3-month CDP within a time interval from time 0 (random-
ization) to t∗ (e.g. 2 years) among the subgroup of EXPAND patients who would not relapse
between randomization and t∗ regardless of treatment assignment. The critical distinction
between this estimand and one based purely on observed occurrence of on-study relapse is
that the principal stratum estimand is defined in terms of potential outcomes and is hence
a proper subgroup.
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3 Principal stratum estimand
In this section, we provide a mathematical representation of the estimand defined in Section
2 and discuss the extent to which it can be identified from the observed data.
3.1 Principal stratification
The principal strata are defined in terms of potential outcomes, see for example (Neyman,
1923; Rubin, 1974). Let Z = 0, 1 be an indicator variable denoting treatment assignment,
with 0 and 1 corresponding to control and active treatment, respectively. For this exposition,
we consider a fixed time-interval of interest from time t = 0 (randomization) to time t = t∗,
e.g. 12 or 24 months after randomization. Now, define for each subject the following binary
potential outcomes:
• S(z) = occurrence of relapse over the period [0, t∗] under treatment z = 0, 1;
• Y (z) = occurrence of CDP over the period [0, t∗] under treatment z = 0, 1.
Note that all subjects have a pair of potential outcomes, only one of which is observed
(i.e. the potential outcome corresponding to the treatment actually assigned). Also note that
in a randomized trial, the potential outcomes are independent of the treatment assignment.
Finally, we denote by S and Y the corresponding observed outcomes for the intercurrent
event and the primary outcome, respectively.
We now define four principal strata based on the potential outcomes S(z):
• Immune (I): Subjects that would not experience relapse regardless of treatment
assignment, i.e. S(0) = S(1) = 0;
• Doomed (D): Subjects that would experience relapse regardless of treatment assign-
ment, i.e. S(0) = S(1) = 1;
• Benefiter (B): Subjects that would only experience relapse if treated with control,
i.e. S(0) = 1, S(1) = 0;
• Harmed (H): Subjects that would only experience relapse if treated with the active
treatment, i.e. S(0) = 0, S(1) = 1.
As discussed above, randomization ensures that the potential outcomes S(0) and S(1)
are jointly independent of treatment assignment, i.e. {S(0), S(1)} ⊥ Z. In other words, the
value of the pair {S(0), S(1)} is not affected by treatment and can thus be regarded as a
pre-treatment characteristic.
We are now ready to define the estimand of interest:
P [Y (1) = 1|S(0) = 0, S(1) = 0]
P [Y (0) = 1|S(0) = 0, S(1) = 0] =
P [Y (1) = 1| I]
P [Y (0) = 1| I] . (1)
4
This is the principal stratum causal effect of treatment on CDP (expressed as a risk ratio)
in the population of immune patients.
We consider inference about the estimand in Equation (1) using the Bayesian framework;
see Section 4 for the model specification. One could also proceed with estimation using the
frequentist framework, although doing so would likely require several identifying assumptions
in order to produce a point estimate (or one could resort to estimating bounds). It is
nevertheless illuminating to consider the extent to which the estimand is identifiable. We
hence discuss this topic in Section 3.3.
3.2 Assumptions
We make two main assumptions:
Assumption 1 – Joint Exchangeability: Z ⊥ {S(1), S(0), Y (1), Y (0)}. That is, the
treatment assignment is jointly independent of the potential outcomes. In our setting, the
trial is randomized so this assumption holds by design.
Assumption 2 – Monotonicity: For any patient, S(0) = 0 ⇒ S(1) = 0 or, equivalently,
S(1) = 1⇒ S(0) = 1.
The monotonicity assumption rules out the “harmed” principal stratum and allows some
patients to be classified as belonging to exactly one stratum. For example, a patient on the
control arm (Z = 0) with S = 0 must be “immune”, and a patient on the active arm (Z = 1)
with S = 1 must be “doomed”.
The monotonocity assumption warrants careful consideration. It is a partially testable as-
sumption as it implies that P (S(0) = 0) ≤ P (S(1) = 0) and these probabilities are identified
under Assumption 1. In fact, we can rule out Assumption 2 if P (S(0) = 0) > P (S(1) = 0).
However, failure to rule out Assumption 2 does not mean that it is true. Thus, one must
ultimately justify the assumption based on substantive considerations. Analyses that assess
sensitivity to departures from monotonicity may be warranted. We discuss options for such
sensitivity analyses in Section 4.
3.3 Estimand identification
In this section we discuss identifiability of the estimand defined in Equation (1). First,
assumptions 1 and 2 allow identification of the principal strata proportions as follows:
P [D] = P [Doomed] = P [S(1) = 1, S(0) = 1]
= P [S(1) = 1] (monotonitity)
= P [S(1) = 1|Z = 1] (exchangeability)
= P [S = 1|Z = 1] .
The last equation follows from the consistency assumption that is fundamental to causal
inference, see for example Herna´n and Robins (2018). Hence, the proportion of doomed
patients can be estimated by the proportion of patients experiencing the event S in the active
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arm. Similarly, the proportion of immune patients is estimated by P (I) = P (S = 0|Z = 0).
Finally, the proportion of benefiters is simply obtained by P (B) = 1− P (I)− P (D).
Now, we briefly discuss the extent to which the estimand of interest can be identified from
the data. By applying the conditional probability formula, followed by the monotonicity and
exchangeability assumptions, the denominator of Equation (1) is identified as follows:
P [Y (0) = 1| I] = P [Y = 1|S = 0, Z = 0]
Hence the denominator is estimated as the proportion of outcomes Y among control patients
for whom S = 0 in the period of interest. However, the numerator of Equation (1) is not
identifiable because patients for which S(1) = 0 could belong to either the immune stratum
or the benefiter stratum. We will hence derive bounds on the numerator which lead to a
range of feasible values for the estimand of interest.
We can use the law of total probability (making no further assumptions) to write
P [Y (1) = 1| I or B] = P [Y (1) = 1| I]P [I | I or B] + P [Y (1) = 1| B]P [B | I or B]
which can be re-arranged as
P [Y (1) = 1| I] = P [Y (1) = 1| I orB]
P [I | I or B] −
P [B | I or B]
P [I | I or B]P [Y (1) = 1| B] (2)
On the right-hand side of this equation, all quantities except P [Y (1) = 1| B] are identifiable
from the observed data. Specifically, P [Y (1) = 1| I orB] = P [Y = 1|S = 0, Z = 1], and
P [B | I or B] and P [B | I or B] are functions of the identifiable principal strata proportions.
When we evaluate the right-hand side over the theoretical range of values for P [Y (1) = 1| B]
(i.e. 0 to 1), we obtain the range of feasible values for P [Y (1) = 1| I]. If I is large relative to
B (i.e. P [B | I or B]/P [I | I or B] is small) then the range of feasible values will be narrow;
conversely if B is large relative to I then this range will be wide.
In order to further identify the numerator, additional substantive assumptions would be
required. In some settings, for example, it might be reasonable to assume that P [Y (1) =
1| B] ≤ P [Y (1) = 1| D]. This untestable assumption, which says that probability of the
outcome under treatment is lower in the benefiter stratum than the doomed stratum, would
narrow the range further but will not lead to full identifiability. Full identifiability will
ultimately require several additional untestable assumptions which may call into question
the reliability of any conclusions drawn from such an analysis. Rather than imposing addi-
tional assumptions to obtain full identifiability, we will use the Bayesian framework to draw
inference about the target estimand.
4 Modeling and inference
4.1 Statistical model
Let G be a random variable indicating principal stratum membership and define pig = P (G =
g) to be the probability of belonging to stratum g ∈ {I,D,B,H}. Note that we include the
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Table 1: Implied principal strata (PS) and disability model depending on the observed value
for (S, Z).
(S, Z) Implied PS Disability model
(0,0) I or H piI
piI+piH
Bernoulli
(
expit
(
θI(0)
))
+ piH
piI+piH
Bernoulli
(
expit
(
θH(0)
))
(0, 1) I or B piI
piI+piB
Bernoulli
(
expit
(
θI(1)
))
+ piB
piI+piB
Bernoulli
(
expit
(
θB(1)
))
(1, 0) D or B piD
piD+piB
Bernoulli
(
expit
(
θD(0)
))
+ piB
piD+piB
Bernoulli
(
expit
(
θB(0)
))
(1, 1) D or H piD
piD+piH
Bernoulli
(
expit
(
θD(1)
))
+ piH
piD+piH
Bernoulli
(
expit
(
θH(1)
))
harmed (H) stratum in the model specification; the monotonicity assumption is realized with
the use of a strongly informative prior.
Next, define θg(z) = logit
{
P [Y (z) = 1|G = g]} as the stratum-specific probability (on
the logit scale) of the primary outcome under treatment z. The estimand of interest is then
expressed mathematically as expit [θI(1)] / expit [θI(0)].
Let ω be a vector of all model parameters (pig and θg(z)). Working in the Bayesian
framework, the posterior distribution of ω is
p(ω|Y, S, Z) ∝ p(Y, S|Z,ω) · p(ω)
= p(Y |S,Z,ω)︸ ︷︷ ︸
disability model
· p(S|Z,ω)︸ ︷︷ ︸
relapse model
· p(ω)︸︷︷︸
prior
. (3)
The relapse model is given as
p(S|Z,ω) = (1− Z) · Bernoulli(piB + piD) + Z · Bernoulli(piD + piH).
Because each combination of (S,Z) = (s, z) implies membership in one of two principal
strata, the disability model for Y given S = s, Z = z is represented by a mixture of two
Bernoulli distributions. For example, the distribution of Y given S = 0, Z = 1 is (under
consistency and randomization) a mixture of two Bernoullis with respective success proba-
bilities expit [θI(1)] and expit [θB(1)], and mixing proportions piI/(piI+piB) and piB/(piI+piB).
Table 1 spells out the likelihood for every combination of S and Z.
To complete the model specification within the Bayesian framework we need to assign
prior distributions for the parameters. For the stratum probabilities we use a log-odds
scaled categorical distribution with real valued parameters αg. This transformation allows
straightforward incorporation of covariates (see Section 4.2) and improves sampling efficiency
(Carpenter et al., 2017). The principal stratum probabilities pig are then recovered with the
softmax function:
pig = softmax(αg) =
exp(αg)∑
k exp(αk)
, αB = 0 for identifiability.
The softmax function maps the 4-dimensional vector of real numbers α = (αI , αD, αB, αH)
to a 4-dimensional simplex, i.e. ensures that
∑
g pig = 1. We set αB = 0 because the softmax
function is invariant under adding a constant to each component of its input.
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We parameterize the active-arm outcome parameter as θg(1) = θg(0) + ∆g. We then
assume independent weakly informative normal priors for the principal stratum parameters
αI , αD and the outcome parameters θg(0) and ∆g, g ∈ {I,D,B,H}. The specific priors used
in our case study are shown in Section 5.1.
The monotonicity assumption is encoded through the use of a strongly informative prior
on αH with extreme location (relative to a plausible range of the αg parameters) and small
standard deviation. Use of such a prior will essentially imply that P (piH = 0) = 1, and that
this probability will remain equal to 1 in the posterior distribution. Because monotonicity
is enforced through a strongly informative prior, a natural way to assess sensitivity to the
assumption is to gradually relax the prior towards “weaker” forms of monotonicity. To this
end, one could both shift the location of the prior closer to zero and increase the prior
standard deviation to be closer to that used for the other principal strata.
4.2 Inclusion of covariates and handling of missing data
Let X denote a vector of baseline covariates and M be an indicator variable that denotes
whether (Y, S) is missing, i.e., M = 1 if (Y, S) is missing and M = 0 if (Y, S) is observed. We
assume that M is independent of (Y,G) given X, Z. We also note that Z is independent of
(Y (0), Y (1), S(0), S(1),X), due to randomization. To include covariates and handle missing
data, we further index the model parameters from the previous section by X, so that pig,x =
P [G = g|X = x] and expit[θg,x(z)] = P [Y (z) = 1|G = g,X = x]. In (3), the disability and
relapse models are conditioned on X and M = 0, where conditioning on M = 0 follows from
our assumption on the missingness mechanism. Further, p(S|Z,X,M = 0,ω) = (1 − Z) ·
Bernoulli(piB,X+piD,X)+Z ·Bernoulli(piD,X+piH,X), and p(Y |S,Z,X,M = 0,ω) is a Bernoulli
mixture with parameters indexed by X; for example, if (S,Z) = (0, 0), we have a mixture
with parameters expit [θI,X(0)] and expit [θH,X(0)] with mixture weight piI,X/(piI,X + piH,X).
To recover the marginal quantities pig and θg(z), we use the following formulae:
expit [θg(z)] =
1
pig
∫
expit [θg,x(z)] pig,xdF (x), (4)
pig =
∫
pig,xdF (x),
where dF (x) denotes the joint cumulative distribution function of X.
In our case study, we use two dichotomous covariates (see Section 5). We thus obtain
estimates of covariate-specific parameters pig,x and θg,x(z) by fitting (3) separately within each
of the four covariate combinations. In general, if covariates are continuous or have too many
categories to be treated independently, models could be fitted with regression techniques.
For example, the principal stratum parameters could be estimated with multinomial logistic
regression with αg,x = x
′βg where βg is a vector of covariate coefficients corresponding to
principal stratum g.
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5 The EXPAND trial – Principal stratum analysis
In the context of the EXPAND trial, the principal stratum of non-relapsers corresponds
to the immune stratum defined in Section 3. We conducted separate analyses for three
difference choices for time t∗ = 12, 18 and 24 months. Two covariates were used: baseline
EDSS score dichotomized to high (6+) and low (< 6), and occurrence of relapses within 2
years prior to study (yes/no). Hence four covariate strata were obtained.
5.1 Prior distributions
We used the following prior distributions in our analysis:
• αg,x ∼ N(0, 22) for g ∈ {I,D} with the following rationale. Without covariates, a
N(0, 1) prior for αI and αD would imply a prior median of approximately 0.31 for
piI and piD with a prior 95% CI of (0.04, 0.80). This prior does not overly favor
extreme parameter values, nor does it assign excess prior probability to one principal
stratum over another. With covariates, the effective variance reduces by a factor
approximately proportional to the number of covariate combinations (assuming roughly
uniform distribution across covariate groups). To account for this, we thus increase
the prior variance within each covariate by a factor of 4, i.e. use a N(0, 22) prior for
αg,x.
• αH,x ∼ N(−50, 0.12). This prior ensures that piH = 0 with prior probability essentially
equal to 1.
• θg,x(0) ∼ N(logit(0.3), 22), for all g, i.e. identical and independent priors in all principal
strata. The mean of this prior was chosen to reflect the expected two-year disability
rate among untreated patients as described in the EXPAND study protocol. The vari-
ance was motivated with similar reasoning as above; in the absence of covariates, a
N(logit(0.3), 1) prior would imply a prior median disability rate of 0.3 with a 95% CI of
(0.06, 0.75) which well covers the range of plausible values. Since we use two dichoto-
mous covariates, the prior variance within each covariate combination is increased by
a factor of 4.
• With θg,x(1) parameterized as θg,x(0)+∆g,x, ∆g,x represents the difference from placebo
(on a log-odds-ratio scale) when treated with active treatment. For ∆g,x we used a
N(0, 22) prior to represent a prior expectation of no treatment effect, with the variance
motivated exactly as above.
Importantly, we avoided the use of flat non-informative priors (e.g. N(0, 106)) because
such distributions can place a large amount of prior probability on regions of the parameter
space that are highly implausible. For example, a diffuse normal prior for αg would yield
an implied bimodal prior for pig with most of the prior mass concentrated near 0 or 1.
Similarly for θg,x(0), even a moderately diffuse prior (e.g. N(0, 50
2)) implies only a 0.03 prior
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Table 2: Summary statistics for the t∗ = 12 month time point, grouped by anonymized
covariate stratum and randomized treatment assignment. Statistics presented are: number of
patients randomized, number available for analysis, and number of relapses/CDPs observed
between randomization and the given time point.
Cov. stratum Treatment # randomized # available # relapses # CDPs
1 Siponimod 208 167 22 30
1 Placebo 107 81 13 22
2 Siponimod 300 236 15 51
2 Placebo 155 126 17 35
3 Siponimod 180 145 20 20
3 Placebo 95 74 11 18
4 Siponimod 408 317 13 61
4 Placebo 188 137 7 20
probability for the range 0.03 to 0.75 (which is the actual 95% credible interval obtained with
the prior specified above).
To assess sensitivity to departures from monotonicity, we investigated two alternative
prior distributions for αH,x. For “weak monotonicity”, we used a N(−2, 0.52) prior which
implies (in the absence of covariates) a prior median of 0.04 for piH and a prior 95% CI of
(0.01, 0.13). In other words, this prior allows for the possibility that some patients might
belong to the harmed stratum, but assigns low prior probability to this relative to the other
principal strata. For “no monotonicity”, we used the same prior for αH,x as for αI,x and αD,x
(i.e. N(0, 22)). In this setting, the prior probability of belonging to the harmed stratum is
not expected to be any larger or smaller than for the other strata.
Finally, we note that because αB = 0, the implied prior for piB is not identical to those
of piI and piD. Indeed, the prior median for piB is centered at 0.29 and the prior 95% CI is
somewhat narrower. Different priors could be used for αI and αD that would result in a
more “symmetric” prior distribution for pig (piH notwithstanding). For example, a bivariate
normal prior for (αI , αD) with a correlation of 0.5 would result in approximately equal prior
distributions. Working on the natural parameter scale and placing a Dirichlet(1, 1, 1) prior
on (piI , piD, piB) would also achieve the same goal. Both of these prior configurations were
investigated and did not produce results substantially different from those shown in Section
5.3.
5.2 Details on estimation
The model described in Section 4 was fitted using the probabilistic programming language
Stan. This language provides Bayesian inference through Markov chain Monte Carlo (MCMC)
methods using the No-U-Turn sampler (NUTS). See Carpenter et al. (2017) for an overview.
Four chains were simulated each with 1000 warm-up (tuning) iterations and 1000 sampling
iterations which were saved for inference. Chains were randomly seeded, and mixing and
convergence were assessed using graphical methods (e.g. trace plots), diagnostics such as
10
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Figure 1: Posterior probability of belonging to each principal stratum for different times t∗
(12, 18 and 24 months) and under varying assumptions for monotonicity. Shown are pos-
terior medians with 95% credible intervals. The “Definite-relapser” and the “Non-relapser”
principal strata correspond to the “doomed” and “immune” principal strata, respectively, as
discussed in Section 3.
Rhat (Gelman et al., 2013, p. 285) and checking for divergent transitions. Table 2 shows
the summary statistics for the t∗ = 12 month time point, grouped by covariate stratum and
treatment assignment. The Stan model file is provided in an online supplement.
5.3 Results
Estimated principal strata proportions are shown in Figure 1. We see that the posterior
probability of belonging to the non-relapser stratum is substantially larger than that of any
other strata, with median probability of at least 0.8 under monotonocity. As the mono-
tonicity assumption is relaxed, the posterior probability of belonging to the non-relapser
remains the largest among all strata, and that for the harmed stratum is at most (under no
monotonicity) roughly similar to the definite-relapser stratum.
Figure 2 shows inference for the estimand of interest (see Equation (1)). A risk ratio of
< 1 implies a beneficial effect of treatment. Under monotonicity we see a consistent benefit
of treatment with posterior median risk ratios ranging from 0.80 to 0.85, depending on the
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Figure 2: Posterior risk ratios in the non-relapser principal stratum. Shown are posterior
medians (point), and posterior 50% and 95% credible intervals (thick and thin lines, respec-
tively).
time point. Further, there is at least approximately 70–75% posterior probability that the
risk ratio < 1 for both endpoints and all time points. We note that the 95% credible intervals
get wider as t∗ increases. This is largely explained by decreasing number of patients available
for analysis later in the trial (median follow-up time was approximately 18 months).
The estimates remain fairly consistent as the monotonicity assumption is relaxed; pos-
terior medians shift slightly but credible intervals are largely overlapping. While there is
a slight increase in uncertainty (wider credible intervals) with weak or no monotonicity,
it appears that the qualitative conclusions of the analysis do not depend strongly on this
assumption.
6 Discussion
We have proposed a principal stratum estimand to quantify the effect of treatment in the
population of patients that would not experience a post-randomization event based on poten-
tial outcomes. Our work is motivated by an interest in quantifying the efficacy of siponimod
in a non-relapsing population of patients with secondary progressive multiple sclerosis. We
used a Bayesian approach for statistical inference on the principal stratum estimand. This
has the benefit of allowing some structural assumptions to be encoded using informative
priors, which can be easily changed in sensitivity analyses. Furthermore, while the estimand
of interest would be non-identifiable if estimated in the frequentist framework (see Section
3.3), working in the Bayesian framework allows straightforward calculation of the posterior
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distribution and derivation of inferential posterior summaries as long as sensible priors are
used. Care is needed when specifying priors as results could be sensitive to particular choices.
Very diffuse priors may be unintentionally informative in this context, and can also lead to
computational difficulties. We used priors that capture the plausible range of parameter val-
ues. While not central to the methodology developed in this paper, we included covariates
in the context of handling missing data. We used a missing at random assumption here,
while a missing completely at random assumption was made in the companion article by
Cree et al. (2018). Results for both missing data assumptions were comparable.
The draft regulatory guidance document ICH E9(R1) on estimands and sensitivity anal-
yses in clinical trials discusses five strategies (i.e. treatment-policy, hypothetical, while on
treatment, composite, principal stratum) for defining estimands in the presence of post-
randomization events, referred to as “intercurrent” events (ICH, 2017). In this article, we
developed methods associated with the principal stratum strategy in which the intercurrent
event was the occurrence of relapse over a fixed time period and the outcome was disability
progression over the same period. Alternatively, the treatment-policy strategy would define
an estimand that focuses solely on the occurrence of disability progression over a fixed time
period and ignores the intercurrent event (i.e. the intent-to-treat effect). This was the pri-
mary estimand in the EXPAND study. The composite strategy would define a new variable
that combines the intercurrent event and the outcome into a single variable, e.g. no relapse
and no disability progression over a fixed period of time. The estimand would then be the
intention-to-treat effect based on the composite endpoint. The hypothetical strategy would
envisage a setting where relapses do not occur. This would require a precise description
under which conditions this setting may be realistic. Finally, the while relapse-free strat-
egy (corresponding to the while on treatment strategy in ICH (2017)) would define a new
variable, e.g. disability progression prior to relapse.
The estimand framework has been discussed in the literature (Akacha et al., 2017; Leuchs
et al., 2015; Mallinckrodt et al., 2012; Mehrotra et al., 2016). Relatively speaking, the
principal stratum strategy has received less attention. Permutt (2016) in his taxonomy of
estimands highlights that the effect in the principal stratum is “easy to define precisely, if
not to estimate”. Akacha et al. (2017) note that for the principal stratum strategy “more
formal training of clinical statisticians and practical experience is needed”. The EXPAND
study example described in this article provides such a practical example.
The methods developed in this paper apply to binary variables, both in the case of out-
come and for intercurrent event. Extensions for continuously distributed outcome variables
(e.g. normally distributed) are straightforward. Another possible extension would be to
treat both disability and relapse as time-to-event variables, for which one would define S(z)
and Y (z) as the time to relapse and disability under treatment z, respectively. A patient
would be then considered immune up to time t if both S(1) > t and S(0) > t. Survival
distributions FS(z)(·) and FY (z)(·) would need to be defined, for example with parametric or
semi-parametric models. The joint survival distribution FS(z),Y (z)(·, ·) could be modeled with
a copula. Other approaches include (Ding and Lu, 2017), who develop methodology that con-
structs weighted samples based on principal scores, defined as the conditional probabilities
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of the latent principal strata given covariates. Their analysis does not rely on any modeling
assumptions on the outcome variable. However, identification of the principal causal effects
relies on several assumptions, including exclusion-restriction (no effect on the intermediate
variable implies zero effect on the outcome, see e.g. Angrist et al. (1996)), which would not
be an appropriate assumption in our setting.
In this article, we considered the use of principal stratification to assess the treatment
effect in a subgroup who would not relapse regardless of treatment assignment. The methods
developed can be applied, for binary outcomes, to draw inference about the causal effect
among compliers (Little and Kang, 2015) and the causal effect among survivors (Rubin et al.,
2006). The former estimand is highly relevant in the context of non-inferiority or equivalence
trials and the latter estimand in the context of trials in which functional outcomes may be
truncated by death (ICH, 2017).
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